Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvalYear |
2008
|
| gptkbp:ATCCode |
gptkb:B02BX05
|
| gptkbp:brand |
gptkb:Revolade
|
| gptkbp:CASNumber |
496775-61-2
|
| gptkbp:chemicalFormula |
C25H22N4O4
|
| gptkbp:contraindication |
severe hepatic impairment
|
| gptkbp:genericName |
gptkb:eltrombopag
|
| https://www.w3.org/2000/01/rdf-schema#label |
Promacta
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Novartis
|
| gptkbp:mechanismOfAction |
thrombopoietin receptor agonist
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
fatigue headache liver enzyme elevation |
| gptkbp:usedFor |
thrombocytopenia
thrombocytopenia in patients with chronic hepatitis C chronic immune thrombocytopenia severe aplastic anemia |
| gptkbp:bfsParent |
gptkb:Novartis
|
| gptkbp:bfsLayer |
4
|